Skip to content

Study · Randomized controlled trial · n = 667 · 2011

7 results

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF and 4 more

Show all authors

Han L, Piura E, Whelan TJ, Pollak MN

Journal of clinical oncology : official journal of the American Society of Clinical Oncology12 Sept 2011Cited by 62 (Europe PMC)

PMID21911723 (opens in a new tab)DOI10.1200/jco.2010.33.7006 (opens in a new tab)PepBankPUB-21911723
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with early breast cancer, adding octreotide to tamoxifen yielded an EFS hazard ratio of 0.93, without significance.

    In plain wordsIn postmenopausal women with early breast cancer, adding octreotide to tamoxifen did not significantly change event-free survival versus tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    DecreaseEvent hazard for event-free survival
    Study

    n = 667

    Comparator
    tamoxifen alone
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    90 mg monthly · intramuscular · 2 yearsAs given in this study (human).

    Measurements

    EFS HR
    0.93
    95% CI 0.71 to 1.22; P=.62

    Source sentences

    Summary
    Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).
    2 context sentences
    Summary · context
    Among 667 women with a median follow-up of 7.9 years, 220 events occurred-108 with TAM-OCT and 112 with TAM.
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with early breast cancer, adding octreotide to tamoxifen yielded an RFS hazard ratio of 0.84, without significance.

    In plain wordsIn postmenopausal women with early breast cancer, adding octreotide to tamoxifen did not significantly change relapse-free survival versus tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    DecreaseRelapse hazard for relapse-free survival
    Study

    n = 667

    Comparator
    tamoxifen alone
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    90 mg monthly · intramuscular · 2 yearsAs given in this study (human).

    Measurements

    RFS HR
    0.84
    95% CI 0.59 to 1.18; P=.31

    Source sentences

    Summary
    Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with early breast cancer, adding octreotide to tamoxifen yielded an OS hazard ratio of 0.97, without significance.

    In plain wordsIn postmenopausal women with early breast cancer, adding octreotide to tamoxifen did not significantly change overall survival versus tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    DecreaseDeath hazard for overall survival
    Study

    n = 667

    Comparator
    tamoxifen alone
    Analysis
    Secondary
    Outcome group
    Mortality · Cancer
    Studied dose
    90 mg monthly · intramuscular · 2 yearsAs given in this study (human).

    Measurements

    OS HR
    0.97
    95% CI 0.69 to 1.37; P=.86

    Source sentences

    Summary
    Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with early breast cancer, tamoxifen plus octreotide significantly lowered IGF-1 at 4 months.

    In plain wordsIn women with early breast cancer, tamoxifen plus octreotide lowered IGF-1 at four months; the comparison was not stated.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-1 at 4 months
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    90 mg monthly · intramuscularAs given in this study (human).

    Source sentences

    Summary
    At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  5. 05HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with early breast cancer, tamoxifen plus octreotide significantly lowered IGF binding protein 3 at 4 months.

    In plain wordsIn women with early breast cancer, tamoxifen plus octreotide lowered IGF binding protein three at four months; the comparison was not stated.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF binding protein 3 at 4 months
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    90 mg monthly · intramuscularAs given in this study (human).

    Source sentences

    Summary
    At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  6. 06HumanNon-randomized trialEfficacy outcome

    In postmenopausal women with early breast cancer, tamoxifen plus octreotide significantly lowered C-peptide at 4 months.

    In plain wordsIn women with early breast cancer, tamoxifen plus octreotide lowered C-peptide at four months; the comparison was not stated.

    Peptide
    Octreotide
    Outcome
    DecreaseC-peptide at 4 months
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    90 mg monthly · intramuscularAs given in this study (human).

    Source sentences

    Summary
    At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.
  7. 07HumanObservational studySafety outcome

    Among women with normal baseline gallbladder imaging, cholecystectomy occurred in 23.0% with tamoxifen-octreotide versus 1.4% with tamoxifen alone.

    In plain wordsAmong women with normal baseline gallbladder scans, gallbladder removal was more frequent with tamoxifen-octreotide than tamoxifen alone.

    Peptide
    Octreotide
    Outcome
    IncreaseCholecystectomy
    Study

    n: not reported in source

    Comparator
    tamoxifen alone
    Analysis
    Secondary
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    90 mg monthly · intramuscular · 2 yearsAs given in this study (human).

    Measurements

    Cholecystectomy required
    23%
    TAM-OCT; patients with normal baseline gallbladder imaging
    Cholecystectomy required
    1.4%
    TAM alone; patients with normal baseline gallbladder imaging

    Source sentences

    Summary
    Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).
    1 context sentence
    Summary · context
    trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.